1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Gennex Laboratories Limited

Gennex Laboratories Limited

BBSE:GENNEX
8.75
INR
-0.10
(-1.13%)
0.81EPS
13.94P/E
2.59BMarket Cap
Gennex Laboratories Limited
BSE:GENNEX
(Bombay Stock Exchange)

Recent

price

8.75

P/E

ratio

13.94

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
1.51
1.85
2.26
2.77
2.41
2.91
3.16
3.29
4.21
4.19
4.5
4.84
4.45
4.23
6.05
7.6
7.03
Revenue per Share
0.03
0.03
0.03
0.02
0.05
0.18
0.2
0.06
0.17
0.14
0.3
0.31
0.34
0.71
0.8
0.92
0.76
Basic EPS, GAAP
0.1
0.09
-0.18
-0.04
- -
0.16
-0.08
0.18
0.06
-0.15
-0.11
0.82
-1.1
-2.5
-0.87
-3.32
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.84
1.87
1.9
1.91
1.93
2.13
2.33
2.4
2.55
2.69
2.99
3.3
4.55
7.49
8.21
9.16
- -
Book Value per Share
1.84
1.87
1.9
1.91
1.93
2.13
2.33
2.4
2.55
2.69
2.99
3.3
4.2
7.36
8.08
9.04
- -
Tangible Book Value per Share
131
133
133
127
133
133
133
133
133
133
133
127
146
187
227
227
254
Basic Weighted Avg Shares
198
246
299
350
319
386
419
437
558
556
596
612
650
791
1,376
1,727
1,784
Sales/Revenue/Turnover
3.83
4.47
2.44
2.9
3.57
46.37
8.89
3.08
5.6
4.06
9.56
8.3
5.81
18.54
10.7
11.13
13.27
Operating Margin (%)
7
7
8
8
9
8
8
9
10
10
9
8
9
24
20
26
27
Depreciation Expense
4
4
4
2
7
23
27
8
22
19
40
39
49
132
181
210
194
Net Income, GAAP
15.48
42.82
16.36
70.46
22.79
22.96
12.79
42.49
26.64
27.16
20.23
22.98
22.79
20.11
15.2
9.48
7.34
Effective Tax Rate (%)
2.15
1.53
1.32
0.59
2.05
6.06
6.45
1.91
3.98
3.34
6.77
6.41
7.57
16.66
13.18
12.14
10.87
Profit Margin (%)
43
27
28
39
48
65
91
100
117
141
186
230
192
1,215
1,366
1,923
- -
Working Capital
16
2
1
3
2
- -
1
3
- -
- -
- -
- -
163
132
169
434
- -
LT Debt
244
248
252
254
255
282
309
318
338
357
397
438
865
1,765
1,946
2,328
- -
Total Equity
1.64
1.34
1.47
0.74
2.27
44.71
9.78
2.4
6
4.16
9.26
6.74
3.84
7.91
5.8
6.59
- -
Return on Invested Capital (%)
1.64
1.78
2.07
0.96
3.19
8.63
9.34
3.64
7.72
6.09
10.56
9.11
7.56
10.45
10.16
9.28
- -
Return on Capital (%)
1.76
1.53
1.58
0.82
2.57
8.69
9.14
2.67
6.77
5.34
10.71
9.39
7.93
10.51
10.15
10.25
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
360
- -
LT Borrowings
- -
434
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
243
243
243
Market Capitalization
3,474
1,732
2,590

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
2,647
- -
Cash, Cash Equivalents & STI
- -
1,670
- -
Accounts Receivable, Net
- -
436
- -
Inventories
- -
539
- -
Total Current Liabilities
- -
724
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
360
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.72%
48.34%
19.66%
Free Cash Flow
-151.42%
-124.33%
282.86%
Net Income, GAAP
45.71%
48.73%
15.76%
Sales/Revenue/Turnover
17.76%
26.01%
25.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
283
315
377
403
1,376
2026
342
372
404
610
1,727
2027
398
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.21
0.21
0.22
0.14
0.8
2026
0.22
0.21
0.22
0.16
0.92
2027
0.19
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Gennex Laboratories Limited manufactures and sells active pharmaceutical ingredients, bulk drugs, intermediates and biotech products including Guaifenesin, an expectorant; Methocarbamol, a skeletal muscle relaxant; Fexofenadine HCl, an antihistamine; Phenazopyridine HCl, a urinary tract analgesic; Fluconazole, an antifungal; Melitracen HCl, a tricyclic antidepressant; Mephenesin and Chlorphenesin, muscle relaxants; Sertraline HCl, a selective serotonin reuptake inhibitor; and Allopurinol, a xanthine oxidase inhibitor. The company operates manufacturing facilities in IDA Bollaram and registered office in Hyderabad, Telangana, India, with exports to markets including Algeria, Bangladesh, Brazil, Colombia, Egypt, Germany, Iran, Peru, Saudi Arabia, Spain, Thailand and Vietnam. Incorporated in 1985 as Pharmasia Drugs and Chemicals Private Limited and renamed from Prudential Pharmaceuticals Limited, Gennex Laboratories maintains ISO 9001:2008, ISO 14001 and OHSAS 18001 certifications. Its subsidiary Deccan Remedies Limited received approval from the Drugs Control Administration, Government of Andhra Pradesh, in 2025 for manufacturing additional products under Form 25, valid until May 2028 for domestic and export purposes; the company allotted over 155 lakh equity shares upon conversion of warrants to promoter group members on a preferential basis in June, July and November 2025; and appointed Sandeep Kumar Daga as additional non-executive non-independent director while noting resignations of directors including Dr. S Ch Dharma Rao and Mohammed Khaleequr Rahman in 2025.